{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:18:52Z","timestamp":1771474732995,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1038\/s41433-020-0879-z","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T13:03:43Z","timestamp":1587733423000},"page":"490-498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Management of conjunctival melanoma with local excision and adjuvant brachytherapy"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0854-0859","authenticated-orcid":false,"given":"Niels J.","family":"Brouwer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Marinkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Femke P.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten C. C. M.","family":"Hulshof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley R.","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob J. W.","family":"de Keizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8581-4753","authenticated-orcid":false,"given":"Nanda","family":"Horeweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjam S.","family":"Laman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaco C.","family":"Bleeker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sjoerd G.","family":"van Duinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2261-3820","authenticated-orcid":false,"given":"Martine J.","family":"Jager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7008-4321","authenticated-orcid":false,"given":"Carien L.","family":"Creutzberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregorius P. M.","family":"Luyten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"key":"879_CR1","first-page":"3399","volume":"43","author":"S Tuomaala","year":"2002","unstructured":"Tuomaala S, Eskelin S, Tarkkanen A, Kivela T. Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. Invest Ophthalmol Vis Sci. 2002;43:3399\u2013408.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"879_CR2","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/S0002-9394(02)02288-2","volume":"135","author":"GP Yu","year":"2003","unstructured":"Yu GP, Hu DN, McCormick S, Finger PT. Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol. 2003;135:800\u20136.","journal-title":"Am J Ophthalmol"},{"key":"879_CR3","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/bjo.2009.157933","volume":"93","author":"E Triay","year":"2009","unstructured":"Triay E, Bergman L, Nilsson B, All-Ericsson C, Seregard S. Time trends in the incidence of conjunctival melanoma in Sweden. Br J Ophthalmol. 2009;93:1524\u20138.","journal-title":"Br J Ophthalmol"},{"key":"879_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1586\/17469899.2014.921119","volume":"9","author":"JR Wong","year":"2014","unstructured":"Wong JR, Nanji AA, Galor A, Karp CL. Management of conjunctival malignant melanoma: a review and update. Expert Rev Ophthalmol. 2014;9:185\u2013204.","journal-title":"Expert Rev Ophthalmol"},{"key":"879_CR5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/bjo.77.10.624","volume":"77","author":"P De Potter","year":"1993","unstructured":"De Potter P, Shields CL, Shields JA, Menduke H. Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases. Br J Ophthalmol. 1993;77:624\u201330.","journal-title":"Br J Ophthalmol"},{"key":"879_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1167\/iovs.04-0344","volume":"46","author":"GS Missotten","year":"2005","unstructured":"Missotten GS, Keijser S, De Keizer RJ, De Wolff-Rouendaal D. Conjunctival melanoma in the Netherlands: a nationwide study. Invest Ophthalmol Vis Sci. 2005;46:75\u201382.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"879_CR7","first-page":"1230","volume":"6","author":"P Jovanovic","year":"2013","unstructured":"Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V. Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol. 2013;6:1230\u201344.","journal-title":"Int J Clin Exp Pathol"},{"key":"879_CR8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1136\/bjo.74.10.615","volume":"74","author":"PK Lommatzsch","year":"1990","unstructured":"Lommatzsch PK, Lommatzsch RE, Kirsch I, Fuhrmann P. Therapeutic outcome of patients suffering from malignant melanomas of the conjunctiva. Br J Ophthalmol. 1990;74:615\u20139.","journal-title":"Br J Ophthalmol"},{"key":"879_CR9","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1055\/s-0028-1109651","volume":"226","author":"L Krause","year":"2009","unstructured":"Krause L, Mladenova A, Bechrakis NE, Kreusel KM, Plath T, Moser L, et al. Treatment modalities for conjunctival melanoma. Klin Monbl Augenheilkd. 2009;226:1012\u20136.","journal-title":"Klin Monbl Augenheilkd"},{"key":"879_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/ICU.0000000000000468","volume":"29","author":"D Reichstein","year":"2018","unstructured":"Reichstein D, Karan K. Plaque brachytherapy for posterior uveal melanoma in 2018: improved techniques and expanded indications. Curr Opin Ophthalmol. 2018;29:191\u20138.","journal-title":"Curr Opin Ophthalmol"},{"key":"879_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1055\/s-0029-1246068","volume":"228","author":"H Westekemper","year":"2011","unstructured":"Westekemper H, Schallenberg M, Tomaszewski A, Nuckel H, Sauerwein W, Meller D, et al. Malignant epibulbar tumours: new strategies in diagnostics and therapy. Klin Monbl Augenheilkd. 2011;228:780\u201392.","journal-title":"Klin Monbl Augenheilkd"},{"key":"879_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/01.IOP.0000056020.66654.33","volume":"19","author":"JA Shields","year":"2003","unstructured":"Shields JA, Shields CL, Freire JE, Brady LW, Komarnicky L. Plaque radiotherapy for selected orbital malignancies: preliminary observations: the 2002 Montgomery Lecture, part 2. Ophthal Plast Reconstr Surg. 2003;19:91\u20135.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"879_CR13","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1136\/bjophthalmol-2017-311082","volume":"102","author":"NJ Brouwer","year":"2018","unstructured":"Brouwer NJ, Marinkovic M, van Duinen SG, Bleeker JC, Jager MJ, Luyten GPM. Treatment of conjunctival melanoma in a Dutch referral centre. Br J Ophthalmol. 2018;102:1277\u201382.","journal-title":"Br J Ophthalmol"},{"key":"879_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejca.2016.09.009","volume":"68","author":"M Marinkovic","year":"2016","unstructured":"Marinkovic M, Horeweg N, Fiocco M, Peters FP, Sommers LW, Laman MS, et al. Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome. Eur J Cancer. 2016;68:106\u201313.","journal-title":"Eur J Cancer"},{"key":"879_CR15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1148\/110.3.681","volume":"110","author":"F Ellis","year":"1974","unstructured":"Ellis F, Sorensen A. A method of estimating biological effect of combined intracavitary low dose rate radiation with external radiation in carcinoma of the cervix uteri. Radiology. 1974;110:681\u20136.","journal-title":"Radiology"},{"key":"879_CR16","doi-asserted-by":"crossref","unstructured":"Coupland SE, Barnhill RL, Conway M, Damato B, Esmaeli B, Albert DM. Conjunctival melanoma. In: Amin MB ES, Green F, editors. AJCC canger staging manual, 8th ed. New York: Springer; 2017. p. 795\u2013803.","DOI":"10.1007\/978-3-319-40618-3_66"},{"key":"879_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343\u20136.","journal-title":"Control Clin Trials"},{"key":"879_CR18","first-page":"570","volume":"89","author":"SJ Supe","year":"1963","unstructured":"Supe SJ, Cunningham JR. A physical study of a strontium 90 beta-ray applicator. Am J Roentgenol Radium Ther Nucl Med. 1963;89:570\u20134.","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"879_CR19","doi-asserted-by":"publisher","first-page":"349162","DOI":"10.1155\/2013\/349162","volume":"2013","author":"VM Cohen","year":"2013","unstructured":"Cohen VM, Papastefanou VP, Liu S, Stoker I, Hungerford JL. The use of strontium-90 Beta radiotherapy as adjuvant treatment for conjunctival melanoma. J Oncol. 2013;2013:349162.","journal-title":"J Oncol"},{"key":"879_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1055\/s-2008-1027432","volume":"225","author":"L Krause","year":"2008","unstructured":"Krause L, Ritter C, Wachtlin J, Kreusel KM, Hocht S, Foerster MH. et al. Recurrence rate following adjuvant strontium-90 brachytherapy after excision of conjunctival melanoma. Klin Monbl Augenheilkd. 2008;225:649\u201352.","journal-title":"Klin Monbl Augenheilkd"},{"key":"879_CR21","doi-asserted-by":"publisher","unstructured":"Missotten GS, De Keizer RJ, Spileers W, Blank L. Strontium brachytherapy in conjunctival melanoma (abstract). Acta Ophthalmol. 2011;89:s248. https:\/\/doi.org\/10.1111\/j.1755-3768.2011.4262.x.","DOI":"10.1111\/j.1755-3768.2011.4262.x"},{"key":"879_CR22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/eye.2008.154","volume":"23","author":"B Damato","year":"2009","unstructured":"Damato B, Coupland SE. An audit of conjunctival melanoma treatment in Liverpool. Eye. 2009;23:801\u20139.","journal-title":"Eye"},{"key":"879_CR23","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0161-6420(00)00061-0","volume":"107","author":"CE Stannard","year":"2000","unstructured":"Stannard CE, Sealy GR, Hering ER, Pereira SB, Knowles R, Hill JC. Malignant melanoma of the eyelid and palpebral conjunctiva treated with iodine-125 brachytherapy. Ophthalmology. 2000;107:951\u20138.","journal-title":"Ophthalmology"},{"key":"879_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1442-9071.2010.02469.x","volume":"39","author":"R Karim","year":"2011","unstructured":"Karim R, Conway RM. Conservative resection and adjuvant plaque brachytherapy for early-stage conjunctival melanoma. Clin Exp Ophthalmol. 2011;39:293\u20138.","journal-title":"Clin Exp Ophthalmol"},{"key":"879_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000310419","volume":"207","author":"M Zehetmayer","year":"1993","unstructured":"Zehetmayer M, Menapace R, Kulnig W. Combined local excision and brachytherapy with ruthenium-106 in the treatment of epibulbar malignancies. Ophthalmologica. 1993;207:133\u20139.","journal-title":"Ophthalmologica"},{"key":"879_CR26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/BF03163971","volume":"5","author":"G Langmann","year":"1991","unstructured":"Langmann G, Faschinger C, Kleinert R, Poier E, Langmann A. Zur bulbuserhaltenden therapie von Bindehautmelanomen. Spektrum Augenheilkd. 1991;5:266\u20139.","journal-title":"Spektrum Augenheilkd"},{"key":"879_CR27","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00066-007-1734-x","volume":"183","author":"G Mossbock","year":"2007","unstructured":"Mossbock G, Rauscher T, Winkler P, Kapp KS, Langmann G. Impact of dose rate on clinical course in uveal melanoma after brachytherapy with ruthenium-106. Strahlenther Onkol. 2007;183:571\u20135.","journal-title":"Strahlenther Onkol"},{"key":"879_CR28","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/bjo.2005.068460","volume":"89","author":"R van Ginderdeuren","year":"2005","unstructured":"van Ginderdeuren R, van Limbergen E, Spileers W. 18 years\u2019 experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma. Br J Ophthalmol. 2005;89:1306\u201310.","journal-title":"Br J Ophthalmol"},{"key":"879_CR29","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1136\/bjophthalmol-2014-305055","volume":"98","author":"M Fili","year":"2014","unstructured":"Fili M, Lundell G, Lundell M, Seregard S. High dose rate and low dose rate ruthenium brachytherapy for uveal melanoma. No association with ocular outcome. Br J Ophthalmol. 2014;98:1349\u201354.","journal-title":"Br J Ophthalmol"},{"key":"879_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ijrobp.2005.02.017","volume":"63","author":"B Damato","year":"2005","unstructured":"Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys. 2005;63:385\u201391.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"879_CR31","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.ophtha.2011.01.060","volume":"118","author":"LC Ditta","year":"2011","unstructured":"Ditta LC, Shildkrot Y, Wilson MW. Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences. Ophthalmology. 2011;118:1754\u20139.","journal-title":"Ophthalmology"},{"key":"879_CR32","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1007\/s00417-004-1080-y","volume":"243","author":"M Kurli","year":"2005","unstructured":"Kurli M, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years\u2019 experience. Graefes Arch Clin Exp Ophthalmol. 2005;243:1108\u201314.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"879_CR33","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/bjo.2009.176099","volume":"94","author":"HC Russell","year":"2010","unstructured":"Russell HC, Chadha V, Lockington D, Kemp EG. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol. 2010;94:1316\u201321.","journal-title":"Br J Ophthalmol"},{"key":"879_CR34","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/bjophthalmol-2018-312018","volume":"103","author":"NJ Brouwer","year":"2019","unstructured":"Brouwer NJ, Marinkovic M, Luyten GPM, Shields CL, Jager MJ. Lack of tumour pigmentation in conjunctival melanoma is associated with light iris colour and worse prognosis. Br J Ophthalmol. 2019;103:332\u20137.","journal-title":"Br J Ophthalmol"},{"key":"879_CR35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/eye.2012.241","volume":"27","author":"C Stannard","year":"2013","unstructured":"Stannard C, Sauerwein W, Maree G, Lecuona K. Radiotherapy for ocular tumours. Eye. 2013;27:119\u201327.","journal-title":"Eye"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41433-020-0879-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-020-0879-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-020-0879-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:11:10Z","timestamp":1684617070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-0879-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["879"],"URL":"https:\/\/doi.org\/10.1038\/s41433-020-0879-z","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,24]]},"assertion":[{"value":"20 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}